ADC Therapeutics SA (ADCT) Reports Q3 Loss, Tops Revenue Estimates
ADC Therapeutics reported a quarterly loss of $0.16 per share, compared with the Zacks consensus estimate of a $0.21 loss and a $0.30 loss per share a year earlier. The headline also says the company topped revenue estimates.
Why it matters — ADCT watchers may note that the reported per-share loss was narrower than the consensus estimate and the prior-year loss.